Metabolomic Profiling and Drug Interaction Characterization Reveal Riboflavin As a Breast Cancer Resistance Protein–Specific Endogenous Biomarker That Demonstrates Prediction of Transporter Activity In VivoYueping Zhang, Hong Shen, Petia Shipkova et al.|Drug Metabolism and Disposition|2023Cited by 15
A Pilot Study To Assess the Suitability of Riboflavin As a Surrogate Marker of Breast Cancer Resistance Protein in Healthy ParticipantsHong Shen, Michael Sinz, Nian Tong et al.|Journal of Pharmacology and Experimental Therapeutics|2024Cited by 15